KR101747476B1 - 마취 제제 - Google Patents

마취 제제 Download PDF

Info

Publication number
KR101747476B1
KR101747476B1 KR1020127021761A KR20127021761A KR101747476B1 KR 101747476 B1 KR101747476 B1 KR 101747476B1 KR 1020127021761 A KR1020127021761 A KR 1020127021761A KR 20127021761 A KR20127021761 A KR 20127021761A KR 101747476 B1 KR101747476 B1 KR 101747476B1
Authority
KR
South Korea
Prior art keywords
cyclodextrin
anesthetic
alpacalone
delete delete
nerve stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127021761A
Other languages
English (en)
Korean (ko)
Other versions
KR20120136347A (ko
Inventor
줄리엣 마궤라이트 굳차일드
콜린 스탠리 굳차일드
벤자민 제임스 보이드
Original Assignee
드로브리지 파마슈티컬스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 드로브리지 파마슈티컬스 피티와이 엘티디 filed Critical 드로브리지 파마슈티컬스 피티와이 엘티디
Publication of KR20120136347A publication Critical patent/KR20120136347A/ko
Application granted granted Critical
Publication of KR101747476B1 publication Critical patent/KR101747476B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127021761A 2010-01-21 2011-01-19 마취 제제 Active KR101747476B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (2)

Publication Number Publication Date
KR20120136347A KR20120136347A (ko) 2012-12-18
KR101747476B1 true KR101747476B1 (ko) 2017-06-14

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127021761A Active KR101747476B1 (ko) 2010-01-21 2011-01-19 마취 제제

Country Status (27)

Country Link
US (2) US8697678B2 (cg-RX-API-DMAC10.html)
EP (1) EP2525798B1 (cg-RX-API-DMAC10.html)
JP (1) JP5930311B2 (cg-RX-API-DMAC10.html)
KR (1) KR101747476B1 (cg-RX-API-DMAC10.html)
CN (1) CN102802635B (cg-RX-API-DMAC10.html)
AU (1) AU2011207103B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012017800B1 (cg-RX-API-DMAC10.html)
CA (1) CA2786762C (cg-RX-API-DMAC10.html)
CL (1) CL2012002032A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119947T1 (cg-RX-API-DMAC10.html)
DK (1) DK2525798T3 (cg-RX-API-DMAC10.html)
ES (1) ES2646829T3 (cg-RX-API-DMAC10.html)
GB (2) GB2491491B (cg-RX-API-DMAC10.html)
HR (1) HRP20171699T1 (cg-RX-API-DMAC10.html)
HU (1) HUE035441T2 (cg-RX-API-DMAC10.html)
LT (1) LT2525798T (cg-RX-API-DMAC10.html)
NO (1) NO2525798T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ601255A (cg-RX-API-DMAC10.html)
PL (1) PL2525798T3 (cg-RX-API-DMAC10.html)
PT (1) PT2525798T (cg-RX-API-DMAC10.html)
RS (1) RS56576B1 (cg-RX-API-DMAC10.html)
RU (1) RU2574022C2 (cg-RX-API-DMAC10.html)
SG (1) SG181997A1 (cg-RX-API-DMAC10.html)
SI (1) SI2525798T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201700518T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011088503A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201205370B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JP2018504420A (ja) * 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
US11472833B2 (en) 2018-07-03 2022-10-18 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
KR20210102936A (ko) * 2018-12-10 2021-08-20 헤일로 사이언스 엘엘씨 안정적인 마취제 제제 및 관련 복용량 형태
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020395254B2 (en) 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN115103591B (zh) 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017711A1 (en) 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
US20030073665A1 (en) 2001-03-20 2003-04-17 Thompson Diane O. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE100712T1 (de) * 1989-05-24 1994-02-15 Innovet Inc Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017711A1 (en) 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
US20030073665A1 (en) 2001-03-20 2003-04-17 Thompson Diane O. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
AU2011207103A1 (en) 2012-07-26
HK1169031A1 (en) 2013-01-18
RU2574022C2 (ru) 2016-01-27
PL2525798T3 (pl) 2018-05-30
US8975245B2 (en) 2015-03-10
US20140066417A1 (en) 2014-03-06
HUE035441T2 (en) 2018-05-02
CY1119947T1 (el) 2018-12-12
BR112012017800A2 (en) 2018-07-10
DK2525798T3 (da) 2017-11-20
US8697678B2 (en) 2014-04-15
HRP20171699T1 (hr) 2018-01-26
SI2525798T1 (en) 2018-01-31
EP2525798A4 (en) 2014-02-19
GB2491491B (en) 2014-07-30
PT2525798T (pt) 2017-11-15
SMT201700518T1 (it) 2018-01-11
ES2646829T3 (es) 2017-12-18
GB2484244A (en) 2012-04-04
GB2484244B (en) 2012-10-31
LT2525798T (lt) 2018-01-10
NZ601255A (en) 2013-09-27
ZA201205370B (en) 2013-09-25
KR20120136347A (ko) 2012-12-18
BR112012017800B1 (pt) 2020-12-08
US20120316146A1 (en) 2012-12-13
RU2012134321A (ru) 2014-02-27
JP5930311B2 (ja) 2016-06-08
SG181997A1 (en) 2012-08-30
WO2011088503A1 (en) 2011-07-28
GB201201842D0 (en) 2012-03-21
CL2012002032A1 (es) 2012-12-21
EP2525798B1 (en) 2017-08-09
RS56576B1 (sr) 2018-02-28
NO2525798T3 (cg-RX-API-DMAC10.html) 2018-01-06
JP2013517299A (ja) 2013-05-16
GB2491491A (en) 2012-12-05
EP2525798A1 (en) 2012-11-28
CA2786762C (en) 2017-12-05
AU2011207103B2 (en) 2013-03-21
BR112012017800A8 (pt) 2018-08-14
CN102802635A (zh) 2012-11-28
CA2786762A1 (en) 2011-07-28
CN102802635B (zh) 2014-07-30
GB201210657D0 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
JP5930311B2 (ja) 麻酔薬製剤
EP2785352B1 (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
CN107810000B (zh) 来氟米林的可注射药物组合物
EP3556349B1 (en) Parenteral liquid preparation comprising carbamate compound
JP5462797B2 (ja) 注射可能なメクリジン製剤および方法
AU2013200895C1 (en) Anaesthetic formulation
EP3407899B1 (de) Immunprophylaxe bei rezidivierenden bakteriellen infektionen
AU2014200491A1 (en) Anaesthetic formulation
CA3046458C (en) Parenteral liquid preparation comprising carbamate compound
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10